Senseonics Tests New Transmitter-Free Glucose Monitor

The new system integrates sensors and communication into one unit for adults managing diabetes.

Updated on Oct. 26, 2026 in Diabetes

Bold vector editorial illustration of a sleek metallic implantable medical sensor with a subtle internal glow, set against a clean background. — Senseonics has initiated its first-in-human clinical trial for the Freedom system, an implantable glucose monitor that removes the need for external hardware. AI Illustration. Upload story photo >

Live Poll

Would you prefer a medical monitoring device that requires no external wearable components?

Senseonics has begun its first-in-human clinical study for the Freedom continuous glucose monitoring system. This device is designed to operate without an external on-body transmitter by integrating a battery and Bluetooth technology directly into the sensor.

Why it matters

The development aims to refine glucose monitoring technology for individuals managing diabetes by eliminating the need for bulky external hardware. This early-stage study serves to inform a larger pivotal trial expected in 2027.

Preclinical testing evaluated the device using over 18,500 communication data points, resulting in a 100% success rate for the preferred antenna design. The current first-in-human study is designed to assess device safety and functionality in a clinical setting.

The players

Senseonics

A medical technology company based in Germantown that specializes in long-term implantable continuous glucose monitoring systems.

The details

The Freedom system utilizes the same sensing core as the existing Eversense 365. By embedding the battery and Bluetooth antenna directly within the implantable sensor, the system functions independently of external body-worn transmitters. Researchers are now testing these direct communication capabilities to ensure stable data transmission through human tissue.

October 26, 2026: The first-in-human clinical study initiated.
2027: Senseonics plans to begin a pivotal clinical study.
2028: A potential commercial launch is targeted for the system.

Health Landscape

The development follows the industry trend of miniaturizing diabetes management tools to improve patient comfort and compliance. This project marks a shift from existing technologies like the Eversense 365, which rely on external transmitters to relay glucose data to devices.

While this device is currently in early-stage trials, it represents a potential future option for simplifying glucose monitoring routines. Those interested in emerging CGM technologies should discuss current sensor options and future management preferences with their endocrinologist.

The takeaway

This system highlights the ongoing evolution toward fully internal, low-profile glucose monitoring solutions. As these technologies move through clinical phases, readers should continue to monitor their current glucose levels using validated devices recommended by their healthcare provider.